Skip to main content
. Author manuscript; available in PMC: 2023 Aug 30.
Published in final edited form as: Sci Transl Med. 2022 Aug 17;14(658):eabq4130. doi: 10.1126/scitranslmed.abq4130

Fig. 6. AS03-adjuvanted RBD-nanoparticle vaccination confers protection against SARS-CoV-2 Omicron challenge.

Fig. 6.

(A) SARS-CoV-2 Omicron viral load in BAL fluid was measured using N gene subgenomic PCR. (B and C) SARS-CoV-2 Omicron viral load in nasal swabs was measured using N (B) and E (C) gene subgenomic PCR. (D and E) Peak N gene viral load in the BAL fluid (D) and nasal swabs (E) was measured. Data are presented as box plots in which the boxes show median and 25th to 75th percentiles and the whiskers show the range. The statistical differences between groups were determined using Mann-Whitney test. The dashed horizontal lines indicate the lower limit of quantitation. (F) Spearman’s correlation between serum IgG response measured before challenge (the time point closest to the challenge) and peak BAL fluid viral load is shown.